The introduction of 750mcg teriparatide therapy in Australia has involved significant sales . Currently, it’s primarily offered for patients with severe osteoporosis that other therapies have proven inadequate . Securing this more potent formulation can be restricted due to healthcare prescription requirements and limited clinic supply . While ce